萘二磺酸氯吡格雷(Clopidogrel napadisilate) - 药物靶点：P2Y12 receptor_在研适应症：血栓形成_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Clopidogrel、Clopidogrel napadisilate monohydrate、Pidogul

+ [1]

靶点

P2Y12 receptor

作用方式

拮抗剂

作用机制

P2Y12 receptor拮抗剂(嘌呤P2Y12受体拮抗剂)

治疗领域

心血管疾病

在研适应症

血栓形成

非在研适应症-

原研机构

Hanmi Pharmaceutical Co., Ltd.

在研机构

Hanmi Pharmaceutical Co., Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

英国 (2010-12-23),

血栓形成

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C16H16ClNO2S

InChIKeyGKTWGGQPFAXNFI-HNNXBMFYSA-N

CAS号113665-84-2

查看全部结构式(2)

关联

167

项与萘二磺酸氯吡格雷相关的临床试验

ISRCTN16705062

/ Recruiting临床4期IIT

Antiplatelet Secondary Prevention International Randomised study after INtracerebral haemorrhaGe (ASPIRING): an investigator-initiated, multicentre, pragmatic, prospective, randomised, parallel group, open clinical trial of an investigational medicinal product

开始日期2025-03-01

申办/合作机构

The University of Edinburgh

SLCTR/2024/038

/ SuspendedN/A

Can a higher dose overcome clopidogrel resistance – a study of 150mg daily, in patients with abnormal platelet function with and without cyp2c19 gene polymorphism

开始日期2024-12-01

申办/合作机构

Medical Research Institute

NCT06613191

/ Not yet recruiting临床4期IIT

P2Y12 Inhibitor Versus Aspirin Monotherapy in Patients Undergoing Elective Screening and Surveillance Colonoscopy

Patients on dual antiplatelet therapy )aspirin plus a P2Y12 inhibitor [clopidogrel, prasugrel, or ticagrelor]) undergoing screening or surveilance colonoscopy are at increased risk for bleeding from the procedure. Patients are ussually asked to stop the P2Y12 inhibitor for the procedure. Currently, recommendation is that patients only on a P2Y12 inhibitor be changes to aspirin for the procedure. This pilot study will evaluate if there is a large difference in bleeding between patients only taking aspirin compared with patients only taking a P2Y12 inhibitor. Patinets who participate will randomly be randomly asked to stop either aspirin or the P2Y12 inhibitor 1 week before the procedure. Periprocedural bleeding and bleeding after the procedure for iup to 30 days.

开始日期2024-10-01

申办/合作机构-

100 项与萘二磺酸氯吡格雷相关的临床结果

登录后查看更多信息

100 项与萘二磺酸氯吡格雷相关的转化医学

登录后查看更多信息

100 项与萘二磺酸氯吡格雷相关的专利（医药）

登录后查看更多信息

10,017

项与萘二磺酸氯吡格雷相关的文献（医药）

2025-03-01·Microchemical Journal

Improved fast reversed-phase HPLC using factorial design for concurrent analysis of ramipril, atorvastatin, and clopidogrel in laboratory synthesized tablet

作者: Rashad, Ethar A. ; Elsayed, Samar S. ; Ibrahim, Fawzia A. ; Nasr, Jenny Jeehan M.

A group of many medical illnesses including diabetes, obesity, hypertension, and dyslipidemia is known to cause a metabolic syndrome leading to an increasing risk of heart disease (HF).In this case, many drugs are required for treatment.Combined therapy is preferred.In this therapy, an anti-hypertensive drug is used with lipid-lowering drugs.Furthermore, antiplatelet and anticoagulant are commonly used to avoid thrombus formation.Therefore, the simultaneous determination of the combination of ramipril (RP), atorvastatin (AT), and clopidogrel (CLP) turns interesting.The objective of this work is to develop a simple, sensitive, and eco-friendly HPLC method to determine this combination effectively.A 2³factorial design model was used for the optimization of chromatog. parameters.A C18 column (150 x 4.6 mm; 5 μm) was used with a mobile phase of Et alc. and 0.05 M sodium dihydrogen phosphate (53:48 volume/volume).The o-phosphoric acid was used to set the pH to 3.The optimal detection wavelength was 210 nm with the flow rate set at 1 mL/min and a run time of 10 min.The application of full factorial design allows the accurate assessment of the drugs under study.The three drugs were eluted within 10 min.The retention times were 2.8 min for ramipril, 5.8 min for atorvastatin, and 8.7 min for clopidogrel.Calibration curves were rectilinear.The linearity range for ramipril was from 0.5to15 μg/mL with a correlation coefficient (r) of 0.9999.The range for atorvastatin was from 0.5to10 μg/mL with (r) 0.9998.The range for clopidogrel was between 0.5 and 30 μg/mL with (r) 0.9999.Concentration values (0.0287, 0.054, and 0.0707) μg/mL were the lowest concentrations detected for RP, AT, and CLP resp.Concentrations (0.0871 0.1637, and 0.2142) μg/mL were the lowest concentrations that can be quantified for RP, AT, and CLP, resp.RP, AT, and CLP were tested simultaneously in both their synthetic mixture and combined tablet formulation.The validation was conducted in agreement with the International Conference on Harmonisation guidelines.

2025-02-01·Molecular and Cellular Biochemistry

The relationship between serum coagulation parameters and the recurrence of chronic subdural hematoma

Article

作者: Xu, Sen ; Liang, Tian-Yu ; Qu, Jian-Min ; Cui, Gang ; Bao, Zhen

The aim is to investigate the relationship between serum coagulation parameters (PT, APTT, D-D and FDP) before hospitalization and recurrence of chronic subdural hematoma (CSDH). 236 patients with CSDH who were diagnosed for the first time and had complete medical records were followed up for at least 90 days. Fifty patients (21.2%) had relapsed. Univariate analysis was conducted including general data, imaging data and test results. Serum coagulation parameters (PT, APTT, D-D and FDP) were detected for all CSDH patients. The study identified several factors that exhibited a significant correlation with chronic subdural hematoma (CSDH) recurrence. These factors included advanced age (p = 0.01), hypertension (p = 0.04), liver disease (p = 0.01), anticoagulant drug use (p = 0.01), antiplatelet drug use (p = 0.02), bilateral hematoma (p = 0.02), and single-layer hematoma (p = 0.01). In addition, the presence of fibrin/fibrinogen degradation products (FDP) exceeding 5 mg/L demonstrated a significant relationship with CSDH recurrence (P < 0.05). Notably, the combined assessment of D-dimer (D-D) and FDP exhibited a significant difference, particularly regarding recurrence within 30 days after surgery (P < 0.05). The simultaneous elevation of serum FDP and D-D levels upon admission represents a potentially novel predictor for CSDH recurrence. This finding is particularly relevant for patients who experience recurrence within 30 days following surgical intervention. Older individuals with CSDH who undergo trepanation and drainage should be closely monitored due to their relatively higher recurrence rate.

2025-02-01·Cell Reports

Platelets tune fear memory in mice

Article

作者: Maggi, Laura ; Mormino, Alessandro ; Ielpo, Donald ; Andolina, Diego ; Chece, Giuseppina ; Catalano, Myriam ; Mazzarella, Letizia ; Di Castro, Maria Amalia ; Limatola, Cristina ; Di Pietro, Erika ; Rinaldi, Arianna ; De Felice, Eleonora ; Garofalo, Stefano ; Stefanini, Lucia ; Cocozza, Germana ; Piacentini, Roberto ; Ventura, Rossella

Several lines of evidence have shown that platelet-derived factors are key molecules in brain-body communication in pathological conditions. Here, we identify platelets as key actors in the modulation of fear behaviors in mice through the control of inhibitory neurotransmission and plasticity in the hippocampus. Interfering with platelet number or activation reduces hippocampal serotonin (5-HT) and modulates fear learning and memory in mice, and this effect is reversed by serotonin replacement by serotonin precursor (5-HTP)/benserazide. In addition, we unravel that natural killer (NK) cells participate in this mechanism, regulating interleukin-13 (IL-13) levels in the gut, with effects on serotonin production by enterochromaffin cells and uptake by platelets. Both NK cells and platelet depletion reduce the activation of hippocampal inhibitory neurons and increase the long-term potentiation of synaptic transmission. Understanding the role of platelets in the modulation of neuro-immune interactions offers additional tools for the definition of the molecular and cellular elements involved in the growing field of brain-body communication.

100 项与萘二磺酸氯吡格雷相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	萘二磺酸氯吡格雷	B01AC04	DB00758

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
血栓形成	英国	Hanmi Pharmaceutical Co., Ltd.	2010-12-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ACS-DM Registry (ESC2023)	N/A	急性冠状动脉综合征 \| 糖尿病	539	Ticagrelor	鬱鹽製壓廠鬱襯憲鹹願(選夢淵襯齋艱艱觸壓繭): HR = 2.53 (95% CI, 1.32 ~ 4.84), P-Value = 0.684 更多	不佳	2023-08-27
				Clopidogrel
ALPHEUS study (ESC2023)	N/A	不稳定型心绞痛	1,866	Ticagrelor	淵顧網襯鹹鹽觸繭願廠(觸選醖窪鹽齋簾糧網觸) = 廠艱鑰襯糧觸膚繭鹽夢願遞製衊夢齋製醖網積 (鹽鏇淵繭獵繭選蓋糧簾 ) 更多	-	2023-08-26
				Clopidogrel	淵顧網襯鹹鹽觸繭願廠(觸選醖窪鹽齋簾糧網觸) = 鏇蓋糧廠構壓醖築艱製願遞製衊夢齋製醖網積 (鹽鏇淵繭獵繭選蓋糧簾 ) 更多
ALPHEUS Naive sub-study (ESC2023)	N/A	不稳定型心绞痛	1,882	Ticagrelor	簾願願鹽憲構鬱醖膚窪(壓鬱獵餘網夢構鹹獵夢) = 構糧壓顧鬱壓範鹹襯壓艱鹹鹽簾餘簾蓋鹹鹹構 (鏇獵夢鬱構齋積齋蓋襯 ) 更多	-	2023-08-26
				Clopidogrel	簾願願鹽憲構鬱醖膚窪(壓鬱獵餘網夢構鹹獵夢) = 餘淵衊積積繭繭夢衊製艱鹹鹽簾餘簾蓋鹹鹹構 (鏇獵夢鬱構齋積齋蓋襯 ) 更多
HOST-EXAM Extended (ESC2023)	N/A	出血 \| 血栓形成维持	-	Clopidogrel	餘蓋醖獵網餘繭膚夢願(鑰夢膚顧醖憲齋築範顧): HR = 2.7 (95% CI, 2.29 ~ 3.18)	-	2023-08-26
				Aspirin
CREA ARIAM Andalucia registry (ESC2022)	N/A	急性冠状动脉综合征	2,070	Ticagrelor	積顧顧簾範齋構範鏇鏇(製襯築蓋窪願襯構構齋) = 構鹹獵鹹網膚醖鹹網淵糧選醖範艱鏇構簾獵憲 (糧積觸餘簾廠鏇鏇糧膚 )	-	2022-08-29
				Clopidogrel	積顧顧簾範齋構範鏇鏇(製襯築蓋窪願襯構構齋) = 襯繭鑰觸襯鬱鹹衊廠鏇糧選醖範艱鏇構簾獵憲 (糧積觸餘簾廠鏇鏇糧膚 )
ESC2022	N/A	急性冠状动脉综合征	-	Clopidogrel SAPT	(鹽鏇憲廠艱蓋範衊廠齋): HR = 0.72 (95% CI, 0.54 ~ 0.98)	-	2022-08-28
				Aspirin monotherapy
ESC2022	N/A	急性冠状动脉综合征	-	Ticagrelor	(製繭獵蓋淵選夢淵蓋糧): HR = 0.9 (95% CI, 0.84 ~ 0.97) 更多	-	2022-08-27
				Clopidogrel
CREA ARIAM Andalucia registry (ESC2022)	N/A	急性冠状动脉综合征	2,070	Ticagrelor	(齋觸窪鑰餘範淵膚醖鹽): adjusted hazard ratio = 1.4 (95% CI, 0.96 ~ 2.05)	-	2022-03-19
				Clopidogrel
CREA-ARIAM Andalucia registry (ESC2022)	N/A	急性冠状动脉综合征	2,070	Ticagrelor	糧艱艱窪鏇蓋觸選選觸(製遞衊衊醖餘網淵範窪) = 築積衊醖製遞醖蓋衊衊淵齋膚憲鬱淵醖鏇艱壓 (積餘蓋窪製構範衊構觸 )	-	2022-03-18
				Clopidogrel	糧艱艱窪鏇蓋觸選選觸(製遞衊衊醖餘網淵範窪) = 簾構壓製醖醖鬱鹹膚構淵齋膚憲鬱淵醖鏇艱壓 (積餘蓋窪製構範衊構觸 )
ISC2022	N/A	-	-	Clopidogrel bolus	夢網壓憲製鏇築廠夢積(選遞餘鏇鏇餘範壓簾鏇) = 淵選憲鬱餘憲餘顧憲壓鏇鏇網觸鹹夢膚廠繭醖 (網觸糧繭遞廠遞鏇遞憲 ) 更多	不佳	2022-02-01
				Sustained clopidogrel pre-treatment	夢網壓憲製鏇築廠夢積(選遞餘鏇鏇餘範壓簾鏇) = 鏇鹹獵顧獵淵鑰糧選構鏇鏇網觸鹹夢膚廠繭醖 (網觸糧繭遞廠遞鏇遞憲 ) 更多